NETTACIN

Posology The dose is 1 or 2 drops into the conjunctival sac of the affected eye(s) 3 times daily, or according to medical prescription. Paediatric population The safety and efficacy of Nettacin 3 mg/ml eye drops, solution in children (under 12 years) and in adolescents (up to 18 years of age) have not been established.

Method of administration 1) Wash/cleanse your hands thoroughly before putting in the eye drops. 2) Open the aluminium sachet containing the single-dose containers. 3) Make sure the single-dose container is intact. 4) Detach one single-dose container from the strip and put the unopened containers back into the sachet.

5) Open by turning the flap of the container without pulling. Do not touch the tip after opening the container. 6) Squeeze the single-dose container gently so that a single drop falls into the affected eye(s). Do not allow the tip of the single-dose container to touch the eye or eyelids, or any other surface, so to avoid possible contamination.

Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa).

Duration of treatment The usual duration of treatment is 5 days. The doctor may recommend a longer treatment in the case of refractory or complicated infections.

The reported undesirable effects are listed below according to MedDRA System Organ classification. There is not enough data available to determine the frequency of the individual effects listed (frequency not known). Eye disorders: - eye irritation - conjunctival hyperaemia - eyelid rash - eyelid oedema - eye pruritus Immune system disorders: - hypersensitivity - urticaria Episodes of eye irritation and hypersensitivity caused by Nettacin are mild and transient.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store).

Serious adverse reactions including neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. 5). Prolonged use of topical antibiotics may determine overgrowth of resistant microorganisms.

If there is no clinical improvement reported within a relatively short period of time or should any irritation or sensitisation phenomena occur, it is necessary to discontinue therapy and start an appropriate treatment. Nettacin is not injectable, therefore it must not be injected subconjunctivally or introduced in the anterior chamber.

During a superficial eye infection, the usage of contact lenses is strongly discouraged. 2).

1.